ADC · PD-1 / PD-L1

7개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved7 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleDaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd)

HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior thera… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
ADCLimited DatastaleCelldex TherapeuticsPhase 2

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

Melanoma · PD-1

#PD-1#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 60Status Discontinued
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#GastricCancer+1
Trials 2Status Active
ADCLimited DatastaleSun Yat-sen UniversityPhase 3

Anti-PD1 combined with Becotatug Vedotin (Anti-PD1 combined with Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase3#antibody-drug-conjugate#Sun
Trials 1Status Recruiting
ADCLimited DatastaleFeng LiuPhase 2

Becotatug Vedotin Combined with PD-1 Inhibitor (Becotatug Vedotin Combined with PD-1 Inhibitor)

Head and Neck Squamous Cell Carcinoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting